Pfizer Buys Option For Vivet In Latest Gene Therapy Tie-Up

The big pharma has acquired a 15% equity stake in the privately-held gene therapy developer and an option to purchase all outstanding shares.

Wooden cubes on table background - Image

The gene therapy business development space has been active, and Pfizer Inc. is the latest to announce a deal in the research area with an option to buy the privately-held French gene therapy developer Vivet Therapeuticss. The companies announced March 20 that Pfizer has acquired a 15% equity stake in Vivet and secured an exclusive license to acquire outstanding shares in exchange for €45m ($51m) up front.

The deal will further expand Pfizer's footprint in gene therapy, where it has been building a significant presence, with several...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.